Related Experiment Videos
Ofloxacin in multidrug resistant tuberculosis
P P Walwaikar1, V K Morye, A S Gawde
1JB Chemicals & Pharmaceuticals Limited, Mumbai 400025.
Journal of the Indian Medical Association
|November 8, 2003
Summary
Tuberculosis (TB) treatment requires new drugs due to rising multidrug-resistant TB (MDR-TB). Ofloxacin shows promise as an effective agent for treating MDR-TB, especially when standard treatments fail.
Area of Science:
- * Infectious Diseases
- * Pharmacology
- * Microbiology
Background:
- * Tuberculosis (TB) remains a leading infectious cause of death globally.
- * Current six-month treatment regimens face challenges from multidrug-resistant TB (MDR-TB) and HIV co-infection.
- * There is a critical need for novel, non-toxic antitubercular agents.
Purpose of the Study:
- * To evaluate ofloxacin as a potential agent for treating multidrug-resistant tuberculosis (MDR-TB).
- * To assess the efficacy of fluoroquinolones in the context of challenging TB treatment scenarios.
Main Methods:
- * Review of in-vitro and in-vivo clinical studies.
- * Analysis of World Health Organization (WHO) recommendations for MDR-TB treatment.
Main Results:
- * Ofloxacin has been identified as a promising agent in both laboratory and clinical settings for MDR-TB.
- * WHO advocates for ofloxacin in specific MDR-TB treatment situations, including empirical therapy and when resistance is confirmed.
Conclusions:
- * Ofloxacin represents a valuable therapeutic option for managing multidrug-resistant tuberculosis (MDR-TB).
- * Its use is particularly recommended when susceptibility results are pending or when resistance to first-line drugs is evident.